The assessment of carryover is a critical, non-negotiable step in LC‑MS/MS clinical assay validation. It is performed by injecting blank samples immediately after high-concentration samples at the upper limit of the measurement interval (ULMI), repeated over multiple analytical runs. The response in the blank must be demonstrably low—typically less than 20% of the signal at the lower limit of measurement interval (LLMI)—to ensure that a preceding high patient sample does not artificially inflate the result of the next specimen.
Carryover is evaluated by monitoring the signal in a blank injected directly after a ULMI calibrator, with an acceptance criterion of <20% of the LLMI response (or zero for critical qualitative markers). When carryover exceeds this limit, it is managed through technical fixes like optimized autosampler wash solvents and extended wash cycles, or through explicit procedural rules for re‑injection.
The Core Evaluation Workflow
Carryover testing is embedded into the system suitability testing (SST) sequence that brackets every validation run. This controlled sequence creates the precise conditions needed to provoke and measure contamination.
Designing the Injection Sequence
The evaluation typically uses a defined SST injection series. A blank diluent is run first to establish a clean baseline. This is followed by an LLMI standard, then a ULMI standard, and an internal standard solution to confirm instrument stability.
After these conditioning injections, the actual carryover test is performed. A blank sample is injected immediately after the ULMI standard, with no intervening washes or blanks. This setup mimics the worst‑case clinical scenario: a patient result just below the reportable limit being followed by a sample that should read negative.
Reproducing the Effect Across Runs
A single observation is not sufficient. The test is repeated across multiple validation batches to assess consistency. Replicates confirm that the carryover level is stable and not a one‑off event driven by a transient autosampler condition. If the carryover response varies significantly between runs, the underlying source is not yet controlled.
Acceptance Criteria That Protect Patient Results
The threshold for an acceptable carryover signal is defined relative to the LLMI, because that’s the concentration where a small contamination event can most easily turn a negative result into a false positive.
Quantitative Analytes: The 20% Rule
For routine quantitative assays, the analyte peak area in the carryover blank must be less than 20% of the peak area observed at the LLMI. This margin ensures that even if a trace of analyte transfers, it stays far below the concentration that would trigger a detectable or clinically meaningful signal above the assay’s reporting limit. It’s a conservative guardband designed to preserve diagnostic accuracy.
Actionable and Qualitative Markers: Zero Tolerance
When the assay detects a marker with immediate clinical or forensic consequences—such as 6‑monoacetylmorphine—the carryover acceptance criterion is stricter. The analyte response in the carryover blank must be completely unobservable. Any detectable peak could lead to a false accusation or incorrect treatment, so the assay must prove an absolute lack of transfer under the test conditions.
Managing Carryover When It Exceeds Limits
If a blank after a ULMI standard shows carryover above the accepted threshold, the assay is not yet fit for clinical use. The fix is always a root‑cause remediation, not a post‑hoc data correction.
Technical Remediations in the Autosampler
The first line of defense is changing the wash protocol. This may involve selecting a more aggressive or tailored autosampler wash solvent—one that efficiently solubilizes the analyte and any matrix components that carry it. If that’s insufficient, the wash cycle volume or duration is extended to allow more thorough flushing of the injection valve, needle, and sample loop. These adjustments directly reduce the residual analyte that can be transferred to the next injection.
Procedural Safeguards for High‑Concentration Samples
When technical fixes cannot eliminate carryover for all possible concentrations, the laboratory must implement explicit standard operating procedure (SOP) rules. The most common rule is mandatory sample re‑injection. If a patient sample is found to have a concentration near or above the ULMI, the next sample in the sequence must be re‑injected from the vial or processed with an intervening blank wash injection. This procedural guard ensures that a reported result is never based on a potentially contaminated injection.
Common Pitfalls to Avoid
Managing carryover is not just about lowering a number. Over‑engineering the solution can create new problems, and misunderstanding the acceptance criteria can lead to false confidence.
The Wash Solvent Trade‑Off
Aggressive wash solvents can introduce their own contaminants or slowly degrade autosampler seals and rotor materials. A solvent that eliminates carryover but causes a rising baseline or a drifting retention time is not an improvement. The goal is effective washing without instrument harm—typically achieved by matching the wash solvent’s elution strength to the analyte’s chemistry without exceeding the LC system’s material tolerances.
Chasing a Zero Risk of Carryover
For quantitative assays, demanding an unobservable carryover signal (below the LLMI) when the analytical goal is simply <20% can waste method‑development time and sacrifice throughput. The risk of a false positive is already negligible at 20% of the LLMI peak area. Reserve zero‑tolerance criteria for the clinically defined qualitative markers where even a faint signal can change a patient’s journey.
Ignoring the Matrix Effect on Carryover
Carryover is not purely an analyte property—it’s a function of the sample matrix. A blank injected after a ULMI standard in pure solvent may show minimal carryover, but the same test with a high‑concentration patient pool or a spiked matrix can produce a different result. If the validation only uses neat standard solutions, it may underestimate real‑world carryover. Always include matrix‑based ULMI challenges where feasible.
Making the Right Choice for Your Assay’s Goal
The carryover evaluation and management strategy you adopt should align with the clinical application and the operational realities of the laboratory. Use this framework to prioritize your efforts.
- If your primary focus is high‑throughput routine testing: Optimize wash solvents and cycle times to meet the <20% LLMI criterion with minimal run‑time extension. Implement the mandatory re‑injection SOP only for samples above a pre‑defined threshold to balance speed and accuracy.
- If your primary focus is a zero‑tolerance forensic or confirmatory marker: Accept the extra cycle time required for an extended, multi‑solvent wash. Validate that the carryover peak is not just below the LLMI but entirely absent from the chromatogram across multiple matrix‑matched runs.
- If your primary focus is a multi‑analyte panel: Test carryover for every analyte individually, as wash solvents that work for one may not work for another. Plan for a compromise wash protocol that keeps the worst‑case analyte below the 20% limit without degrading the performance of the others.
Carryover evaluation is not a box to check—it’s a risk‑management decision that directly safeguards every clinical result your assay will ever produce.
Summary Table:
| Assay Type / Scenario | Carryover Acceptance Criteria | Primary Remediation Strategy |
|---|---|---|
| Quantitative Assays | Analyte peak area in blank < 20% of LLMI response | Optimize autosampler wash solvent & extend wash duration |
| Qualitative / Forensic Markers | Zero tolerance (no observable peak signal) | Implement multi-solvent wash cycles & aggressive elution |
| Out-of-Limit Results | Exceeds established acceptance criteria | Mandatory sample re-injection SOP & intervening blank injections |
Streamline Your Assay Development & Validation with CamelBio
Navigating LC-MS/MS validation and mitigating carryover risks requires reliable materials and expert technical support. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and specialized consulting—covering every stage from concept to clinic.
Whether you need assistance with assay optimization, validation troubleshooting, or sourcing premium components, we are here to support your laboratory's needs. Contact us today to learn more!